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S238 Poster Session IWe have for the first time, using a rapid isolation protocol of EBV-
specific T cells, treated and cured a patient suffering from PTLD
with multiple associated tissue lesions, using her haplo-identical
mother as a donor. This treatment approach paves way for a new pos-
sibility to within days treat patients with life-threatening EBV-asso-
ciated malignancies.215
ALLOGENEIC STEM CELL TRANSPLANTATION WITH REDUCED INTEN-
SITY CONDITIONING AS TREATMENT FOR MATURE T-CELL LYMPHOMAS
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Background: For aggressive lymphomas a T-cell phenotype confers
a poor prognosis. Current therapeutic strategies for T-cell non-
Hodgkin lymphoma (NHL) are poorly defined. Allogeneic stem
cell transplantation (Allo-HCT) is a potentially curative option but
associated with high non-relapse mortality (NRM). Reduced inten-
sity conditioning (RIC) is designed to minimize NRM while using
the benefits of the graft-versus-lymphoma effect. Here we report ret-
rospective analysis of patients with T-cell NHL who underwent
Allo-HCT with RIC using fludarabine and melphalan.
Patients andMethods:A consecutive case-series of 27 patients with
mature T-cell NHLwere included. All patients underwent RICwith
fludarabine and melphalan. Histologies included: PTCL NOS
(n5 5); AILD (n5 3); ALCL (n5 2; both alk+); rare histologies
(n5 6) (NK/T cell, enteropathy type, hepatosplenic); and cutaneous
T-cell lymphomas (n5 11). Most patients (n5 18, 67%) had ad-
vanced disease at the time of transplant: relapse/induction fail-
ure5 17, progression5 1. The rest of the patients were in
CR15 1, CR25 5, PR5 3. The median age was 50 years (range:
19-68), 74% were male (n5 20). The time from diagnosis to trans-
plant for majority of the patients (n5 20, 74%) was more than one
year. The median number of prior regimens was 4 (range: 1-9);
one patient had a prior autologous transplant. All patients received
stem cells, 56% from HLA-matched sibling and 44% from matched
unrelated donor. 18 patients (67%) received GVHD prophylaxis
with sirolimus/tacrolimus, while 9 patients (33%) received cyclo-
sporine/cellcept based prophylaxis.
Results: The median follow-up for the 16 (59%) surviving pa-
tients was 24.2 months (range: 5.6-95.3). Day 100 mortality
was 22% (n5 6). There were a total of 11 deaths; 5 from dis-
ease progression/relapse and 6 from non-relapse causes. 13 pa-
tients (48%) experienced acute GVHD: grade I5 4, grade
II5 5, grade IV5 4. Among the 17 patients who are evaluable
for chronic GVHD, 11 (63%) patients developed an extensive
GVHD. The 2-year probability of overall (OS) and disease-
free (DFS) survival were 55% (95%CI: 43-65%) and 43%
(95%CI: 34-52%) respectively. The relapse/progression and
NRM rates at 2 years were 37% (95%CI: 26-52%) and 28%
(95%CI: 16-46%) respectively.
Conclusion: The overall results show that good long term survival
rates and disease control can be achievedwith acceptable non-relapse
mortality in patients with mature T-cell lymphomas using reduced
intensity conditioning.216
THE IMPORTANCE OF TIMING OF HEMATOPOIETIC STEM CELL TRANS-
PLANTATION (HSCT) IN PATIENTS WITH T-CELL LYMPHOMAS (T-NHL)
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Forest University School of Medicine, Winston-Salem, NC; 2Wake Forest
University School of Medicine, Winston-Salem, NC
Patients (pts) with T-NHL have a poor prognosis with standard
chemotherapy. HSCT have been used in their management but
the most appropriate time for HSCT is not clear. We previously re-
ported the poor outcome of pts with ALK negative (anaplastic lym-
phoma kinase) anaplastic large cell lymphoma (ALCL) having
HSCT after first recurrence (Zamkoff et al, BMT 33:635-8,2004).To further investigate outcomes of pts transplanted for T-NHL,
we retrospectively analyzed 33 pts undergoing autologous HSCT
from August 2000 to July 2009. 23 were male, 10 female; median
age was 53.2 (29 -73) years at time of HSCT. Subtypes of T-NHL
included Alk negative ALCL (9) and Alk positive ALCL (1); periph-
eral T-Cell (PTCL), not otherwise specified (11); Angioimmuno-
blastic (AILT) (9); Nasal NK/T (2) and cutaneous T-cell (CTCL)
(1). 6 pts were in their first complete remission (CR1), 1 in CR1 un-
confirmed (CRU1), 10 in first partial remission (PR1), 9 in first re-
lapse (Rel1) with 8 sensitive and 1 refractory, 3 in CR2, and 4 in
second or later sensitive relapse (Rel2+). Preparative regimens for
HSCT included Cy/TBI (13) or Cy/etoposide/TBI (9), Bu/Cy (6),
CBV (4), and BEAM (1).
Among the 12 pts in CR1/CRU1 or PR1\200 days from diagno-
sis (Group 1), there were 2 with Alk negative ALCL, 5 PTCL, 4
AILT, and 1 Nasal NK/T. Among the 21 pts (Group 2), there
were 7 with Alk negative ALCL, 1 Alk positve ALCL, 6 PTCL, 5
AILT, 1 Nasal NK/T, and 1 CTCL.
With a median follow-up of 17.6 (0.4-84.0) months post
HSCT, the overall survival (OS) is estimated to be 52% and pro-
gression free survival (PFS) is 45%. 16 pts have expired. Causes of
death include relapse (12), transplant related mortality (1), second
malignancy (1), and unknown (2) since no MD follow-up records
available.
Among the 17 surviving pts, 10 were among the 12 pts in
Group 1. For this group, the OS is 83% with a PFS of 75% at
a median follow-up of 18.6 (0.7-60.5) months. 7 additional pts
survive among the Group 2 pts; their OS is 33% and PFS is
29% at a median follow-up of 15.2 (13-84) months. In Group
2, surviving pts include 1 of 3 transplanted in CR2; 6 of 13 trans-
planted in Rel1 or Rel2+ and 0 of 5 in PR1 transplanted .200
days from diagnosis.
In summary, this data would suggest an improved outcome for
HSCT in pts withT-NHLwhen applied earlier in the course of their
disease. Such a strategy should be evaluated in a larger prospective
trial of HSCT in CR1/PR1 to evaluate the efficacy and safety across
the various subtypes T-NHL.217
PREFERENCE OF PATIENTS AND PHYSICIANS CONCERNING TREATMENT
OPTIONS FOR RELAPSED FOLLICULAR LYMPHOMA: A DISCRETE CHOICE
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gary, Calgary, AB, Canada; 2Tom Baker Cancer Centre, Calgary, AB,
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Background: Patients with symptomatic relapsed follicular lym-
phoma, together with their physicians, must choose between a va-
riety of treatment options. The purpose of this study was to elicit
relative preferences for attributes associated with different treat-
ment options amongst lymphoma patients in Alberta, and lym-
phoma-treating physicians in Canada, using a discrete choice
experiment (DCE).
Methods: 180 patients aged 18-65 years and 252 physicians re-
ceived background information and a questionnaire containing
the DCE. Treatment administration, toxicity, average remission
length, and cost were the attributes evaluated for four treatment
options: standard chemotherapy (CT), radioimmunotherapy
(RIT), high-dose chemotherapy and autologous (AUTO) or allo-
geneic (ALLO) stem cell transplantation. In a series of multiple
choice questions, respondents were asked to choose between
two unlabeled treatment options, described according to the attri-
butes where the attribute levels were different for each option.
The DCE was analyzed using a random effects logit model. Mar-
ginal rates of substitution calculated from regression coefficients
provided information about preference for the treatment attri-
butes.
Results: 81 patients (45%) and 48 physicians (19%) completed the
questionnaire. Responding patients had a mean age of 54.7 years
and were on average 4.4 years from initial diagnosis. 93% of patients
Poster Session I S239received prior chemotherapy and 24% had received a prior stem cell
transplant. 48% of patients had not yet relapsed and 33% were cur-
rently symptomatic. Physicians were predominantly hematologists
(93%) who have been in practice on average for 12.2 years. 46% of
physicians reported being in a practice that includes stem cell trans-
plantation. For all participants, remission length was the major pos-
itive influence on choice (p\0.001), and toxicity of ALLO was the
major negative influence (p\0.001). Cost was a significant negative
influence on choice for physicians (p5 0.001), but not for patients.
By post-estimation analysis, patients were most likely to choose
AUTO (69%) and less likely to choose RIT (14%), CT (11%),
and ALLO (7%). The distribution for physicians was similar.
Conclusions: Patients with relapsed follicular lymphoma are able to
consider the advantages and disadvantages of various treatment op-
tions, and most are willing to trade off toxicity, hospitalization,
and cost associated with autologous transplantation in order to ben-
efit from increased remission length.218
CHRONIC GVHD AFTER ALLO-SCT WOULD BE NECESSARY FOR BETTER
OUTCOME OF ALLOGENIC STEMCELL TRANSPLANTATION (ALLO-SCT)
FOR CHEMOREFRACTORY NON-HODGKIN’S LYMPHOMAS -A SINGLE IN-
STITUTE RETROSPECTIVE STUDY
Nakano, N.1,2, Takatsuka, Y.1, Tokunaga, M.1, Takeuchi, S.1,
Kubota, A.1, Tokunaga, M.1, Utsunomiya, A.1 1 Imamura Bun-in Hospi-
tal, Kagoshima, Japan; 2Toranomon Hospital, Tokyo, Japan
Aims:The aims of this study are to identify the feasibility and clinical
characteristics of the patients undergone Allo-SCT for chemo-re-
fractory NHLs.
Design and methods: There were 55 NHL patients who had been
undergone allo-SCT in our institute from August 2001 to March
2009 consecutively. Thirty-seven patients out of 55 were adult T-
cell leukemia/lymphoma (ATLL) patients, and we analyzed about
rest of 18 patents. Study endpoints were 3 years overall survival
(OS), disease free survival (DFS) and these related factors.
Results: Median age was 37.5 yrs (19-63). Thirteen patients were
male and 5 female. Diagnosis included FL (n5 4), PTCL-u
(n5 3), MNKL (n5 3), BL (n5 2), DLBCL (n5 2), ALCL
(n5 1), T-LBL (n5 1), hepatosplenic lymphoma (n5 1), and MF
(n5 1). Median overall survival time and disease free survival time
after SCT were 215.5 days (6-2436) and 73 days (2-2436). Overall
survival rate after SCT was 38.9%. IPI was Low in 2 patients, 8 L-
I, 5 H-I, and 3 High. Low/L-I group showed significantly superior
OS, DFS compare to H-I/High group (54% vs 0%, 56.3% vs 0%).
HCT-CI scoring 0 in 12 patients, five 1, and only one patient scored
over 2. HCT-CI score significantly related to OS after SCT in our
cases. There were 13 sibling donors (included 5HLAhaplo-identical
donors) and 5 unrelated donors (URD) (included 2 cord blood do-
nors) in our cases. Ten patients received myeloablative conditioning
and 8 reduced intensity conditioning (RIC). Disease status at SCT
was CR in 5 patients, 7 PR, and 6 PD. Eleven patients died after
SCT (3 a-GVHD, 2 disease progression, 2 sepsis, 1 TMA, 1 pneu-
monia, 1 invasive aspergirosis, and 1 liver failure). Five patients
died within 100 days after SCT. Six patients have been alive over 3
years (3 yrs OS, DFS: 33.3%, 27.8%). Seven patients were compli-
cated grade 0-1 a-GVHD and 9 grade 2-4. Grade 0-1 group patients
showed significantly superior DFS compare to grade 2-4. Five pa-
tients complained limited c-GVHD and 3 extensive. The patients
group complained with c-GVHD showed better OS and DFS than
asymptomatic group (53.6% vs 12.0%, 58.3% vs 12.5%). Four pa-
tients suffered relapse or progressive disease after SCT. Two out
of these 4 patients showed GVL effect only with reducing immuno-
suppressive therapies.
Conclusion: Allo-SCT would be feasible therapy for chemorefrac-
tory NHLs. Chronic GVHD will be necessary and GVL effect
would be existed in our study.219
PRESENCE OF ABNORMAL PLASMA CELLS IN PERIPHERAL STEM CELL
HARVEST PRODUCTS PREDICT EARLY RELAPSE FOLLOWING AUTOLO-
GOUS STEM CELL TRANSPLANTATION IN PATIENTSWITHMULTIPLEMY-
ELOMA
Bakanay, S.M., Dalva, K., Koksoy, B.E., Civriz, S., Ayyildiz, E.,
Arat, M., Ozcan, M., Ilhan, O., Beksac, M. Ankara University, Ankara,
Turkey
Background: CD38 + 138+ stem cells more than 4.5 x10 5/kg has
been found to shorten overall survival (Kopp, 2009). The EBMT re-
port on the impact of plasma cell cytoreduction in apeheresis prod-
ucts has shown that despite major tumor cell elimination relapse
could not be eliminated(Bourhis, 2007). Flow cytometry has been
claimed to be of lesser specificity than PCR. The multiparametric
flow cytometry has the potential to quantify and distinct normal
plasma cells from abnormal plasma cells. The aim of this prospective
study was to analyze the amount of both normal and abnormal
plasma cells in peripheral stem cell products and correlate with clin-
ical outcome.
Patients: A total of 47 consecutive multiple myeloma patients who
were mobilized between March 2007 and July 2009 were included
in the study. Patients were male/female: 26/21; ISS: I/II/III: 17/
18/11; age: 54 (35 -65). Treatment preceding transplant consisted
of novel agent including protocols (n: 13) or excluding protocols(n:
34). Plasma cell quantification was done using a panel of monoclonal
antibodies by using multiparameter flowcytometry. If any aberrant
expression (such as CD20(loss) CD27(loss) CD28 (gain),
CD33(loss), CD34 (gain), CD81(loss), CD117(gain)) were detected
at diagnosis, the corresponding antibody was also added to the panel.
Results: Abnormal plasma cells were detected in 9 apheresis prod-
ucts from 8 patients. The median plasma cell count (normal plus ab-
normal) was 6.53 (0,19-542) x 105/kg. In the abnormal plasma cell
positive group the median total and abnormal plasma cell counts
were 2.73 (0.19-542) x105/kg and 1.4 (0.07-542) x105/kg, respec-
tively. Twenty five patients had $4.5 x105/kg (high) plasma cells
while 17 patients has\4.5 x105/kg (low) plasma cells.Similar rate
of response (.5 PR) was obtained in 5/7 patients with plasma cell
contamination following transplantation. Amongst 18 patients evalu-
able during post transplant 1 year follow up, 10 of the 12(83%) pa-
tients who had high plasma cell count and 3 of 6 (50%) patients
who had low plasma cell count in their products, either progressed
or relapsed.
Conclusion: High dose therapy with stem cell support may induce
high hematological responses confirmed by reduction inmonoclonal
protein production. Patients who have lower amount of plasma cell
contaminating the apheresis products seem to perform better out-
come during the first year follow up after transplantation.
Table 1.
PostResponse
Pre
Mobilisation
Pre
Transplant
Transplant
month2Relapse
\1 yearAbnormal plasma cell
positive6/7 4/7 5/7 4/7Abnormal plasma cell
negative31/34 27/34 27/32 4/13Total 37/41 31/41 7/39 8/20220
HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANS-
PLANTATION FOR MULTIPLE MYELOMA: WHAT PREDICTS THE OUT-
COME?
Kumar, L., Ganess, P., Gogia, A., Ghosh, I., Hariprasad, R. All India In-
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We analyzed results of 118 patients (84 males and 34 females) of
multiple myeloma who underwent autologous stem cell
